Medicare National Policy On ESAs In Renal Setting Opposed By Physicians, Patients And Amgen
This article was originally published in The Pink Sheet Daily
Executive Summary
They ask CMS, at the very least, to analyze claims data from the agency’s ESA monitoring policy before making any new coverage determinations.
You may also be interested in...
Amgen Shines In Dark Times, Stays Mum On Bone-Drug Plans
After a strong third quarter, execs make analysts wait to hear marketing ideas for denosumab.
Amgen Shines In Dark Times, Stays Mum On Bone-Drug Plans
After a strong third quarter, execs make analysts wait to hear marketing ideas for denosumab.
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call